BiotechTube

SAD448

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ocular Hypertension

Conditions

Ocular Hypertension

Trial Timeline

Apr 1, 2007 → —

NCT ID
NCT00503360

About SAD448

SAD448 is a phase 1 stage product being developed by Novartis for Ocular Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT00503360. Target conditions include Ocular Hypertension.

What happened to similar drugs?

4 of 20 similar drugs in Ocular Hypertension were approved

Approved (4) Terminated (0) Active (16)
✅dorzolamide hydrochloride (+) timolol maleateMerckApproved
✅Netarsudil ophthalmic solution 0.02% + Artificial tearsNovartisApproved
✅latanoprost 0.005% (Xalatan)PfizerApproved
✅DEXTENZA®Ocular TherapeutixApproved
🔄ISV-303Sun PharmaceuticalPhase 3
🔄ISV-303Sun PharmaceuticalPhase 3
🔄STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%Santen PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00503360Phase 1Completed

Competing Products

20 competing products in Ocular Hypertension

See all competitors
ProductCompanyStageHype Score
lotilaner + VehicleTarsus PharmaceuticalsPhase 2
36
Mirabegron + PlaceboAstellas PharmaPhase 1
29
ISV-303 + ISV-303 + DuraSite Vehicle + Xibrom™Sun PharmaceuticalPhase 1/2
32
ISV-303Sun PharmaceuticalPhase 3
40
ISV-303Sun PharmaceuticalPhase 3
40
ONO-9054 + LatanoprostOno PharmaceuticalPhase 2
35
ONO-9054 + PlaceboOno PharmaceuticalPhase 1
29
STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%Santen PharmaceuticalPhase 3
40
Tafluprost, timolol maleateSanten PharmaceuticalPre-clinical
26
DE-111 ophthalmic solutionSanten PharmaceuticalPhase 3
40
DE-117 ophthalmic solution + Latanoprost ophthalmic solution 0.005%Santen PharmaceuticalPhase 3
40
STN1012600 ophthalmic solution 0.002% + Latanoprost ophthalmic solution 0.005%Santen PharmaceuticalPhase 3
40
DE-117 + Latanoprost ophthalmic solutionSanten PharmaceuticalPhase 3
40
DE-117 ophthalmic solution + Timolol ophthalmic solutionSanten PharmaceuticalPhase 3
40
A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL + A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mLSanten PharmaceuticalPhase 3
40
Omaveloxolone Ophthalmic Suspension 1.0% + Omaveloxolone Opthalmic Suspension 0.5% + PlaceboAbbViePhase 2
35
AZD4017 + Placebo + AZD4017 + PlaceboAstraZenecaPhase 2
35
dorzolamide hydrochloride (+) timolol maleateMerckApproved
43
INS115644 Ophthalmic Solution + Placebo + INS115644 Ophthalmic Solution + INS115644 Ophthalmic Solution + INS115644 Ophthalmic SolutionMerckPhase 1
29
MGV354 ophthalmic suspension + MGV354 placeboNovartisPhase 1/2
32